Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
The annual incidence of neuroendocrine tumours in the Caucasian population ranges from 2.5 to 5 new cases per 100,000 inhabitants. Gastroenteropancreatic neuroendocrine tumours is a family of neoplasms widely variable in terms of anatomical location, hormone composition, clinical syndromes they cause and in their biological behaviour. This high complexity and clinical heterogeneity, together with the known difficulty of predicting their behaviour from their pathological features, are reflected in the many classifications that have been developed over the years in this field. This article reviews the main tissue and clinical biomarkers and makes recommendations for their use in medical practice. This document represents a consensus reached jointly by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
KeywordsGastroenteropancreatic neuroendocrine tumours Biomarkers Ki-67 Guidelines Chromogranin A Synaptophysin Octreotide scan
The members of the Working Group on Biomarkers SEOM-SEAP are Ramón Colomer, Pilar García-Alfonso, Pilar Garrido, Ricardo González Cámpora, José Palacios and Enrique de Álava.
Conflict of interest
SEOM and SEAP acknowledge the financial support for this project of unrestricted grants from Pfizer Oncology and Novartis Oncology. Jorge Barriuso has been partially funded by The Spanish Association Against Cancer. The authors state that, at the time of drafting and revision the text of the manuscript, they were unaware of the names of the laboratories who have supported this project, so this support has not influenced the content of this article.
- 4.Lawrence B, Gustafsson BI, Chan A et al (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:1–18, vii.Google Scholar
- 9.Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankfurter Zeitschrift för Pathologie. 1907;1:425–32.Google Scholar
- 17.Bosman F, Carneiro F, Hruban R, et al. WHO classification of tumours of the disgestive system. France: Lyon; 2010.Google Scholar
- 22.La Rosa S, Marando A, Furlan D, et al. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36:601–11.PubMedCrossRefGoogle Scholar
- 34.Kloppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90:162–6.PubMedCrossRefGoogle Scholar
- 46.Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis—a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore). 2001;80:189–222.CrossRefGoogle Scholar
- 48.Lawrence B, Gustafsson BI, Kidd M et al (2011) The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:111–134, viii.Google Scholar
- 57.Bello C, Deprimo SE, Friece C, et al. (2006) Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. ASCO Meeting Abstracts 24:Abstract 4045.Google Scholar
- 58.Rodriguez de Antona C, Grande Pulido E, Leandro-Garcia L, et al. (2012) Evaluation of CYP3A5, VEGF-a, and VEGFR2 polymorphisms as markers of sunitinib toxicity. ASCO Meeting Abstracts 30:Abstract 10546.Google Scholar